Komori
Astellas Pharma (4503) · InitiativeAchieved

Change to the Term of the Pharmaceutical Sales Agreement with トーアエイヨー

First written in FY2022-Q1. 1 of 2 entries say "Achieved", first in FY2022. Latest entry: FY2022.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022-Q12021: 120212022: 12022
Same theme, other companies
Business Impact from Termination or Unfavorable Amendment of Important ContractsA theme 95 companies write about · 101 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 6 of 28 companies on the "Worse" side.

1 other company's latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 95 companies compared. The sentences above are computed from all 95.
Full recordFilings, disclosures and news, newest first
  1. FY2022AchievedAnnual report

    「（注）以下の取引契約を終了しています。・トーアエイヨー株式会社との医薬品の販売契約」

    FY2022-Q1で契約期間変更が開示されていたトーアエイヨーとの医薬品販売契約について、年度末までに終了した。
  2. FY2022-Q1First statedAnnual report

    「当第１四半期連結会計期間において、トーアエイヨー株式会社との医薬品の販売契約の契約期間を変更しました。変更後の契約の概要は以下のとおりです。 契約期間 2022年3月まで」

    トーアエイヨー株式会社との医薬品販売契約の契約期間を変更し、変更後の期間を2022年3月までとした。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.